A citation-based method for searching scientific literature

Iain B McInnes, Proton Rahman, Alice B Gottlieb, Elizabeth C Hsia, Alexa P Kollmeier, Soumya D Chakravarty, Xie L Xu, Ramanand A Subramanian, Prasheen Agarwal, Shihong Sheng, Yusang Jiang, Bei Zhou, Yanli Zhuang, Désirée van der Heijde, Philip J Mease. Arthritis Rheumatol 2021
Times Cited: 18







List of co-cited articles
117 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
Atul Deodhar, Philip S Helliwell, Wolf-Henning Boehncke, Alexa P Kollmeier, Elizabeth C Hsia, Ramanand A Subramanian, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou,[...]. Lancet 2020
108
94

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
Philip J Mease, Proton Rahman, Alice B Gottlieb, Alexa P Kollmeier, Elizabeth C Hsia, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Yanli Zhuang,[...]. Lancet 2020
106
83

Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.
Christopher T Ritchlin, Philip S Helliwell, Wolf-Henning Boehncke, Enrique R Soriano, Elizabeth C Hsia, Alexa P Kollmeier, Soumya D Chakravarty, Federico Zazzetti, Ramanand A Subramanian, Xie L Xu,[...]. RMD Open 2021
13
84

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.
Laura C Coates, Arthur Kavanaugh, Philip J Mease, Enrique R Soriano, Maria Laura Acosta-Felquer, April W Armstrong, Wilson Bautista-Molano, Wolf-Henning Boehncke, Willemina Campbell, Alberto Cauli,[...]. Arthritis Rheumatol 2016
533
55

Psoriatic Arthritis.
Christopher T Ritchlin, Robert A Colbert, Dafna D Gladman. N Engl J Med 2017
603
55

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.
Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, Maarten de Wit, Iain McInnes, Maxime Dougados, Jette Primdahl, Dennis G McGonagle, Daniel Aletaha, Andra Balanescu,[...]. Ann Rheum Dis 2020
295
50


Classification criteria for psoriatic arthritis: development of new criteria from a large international study.
William Taylor, Dafna Gladman, Philip Helliwell, Antonio Marchesoni, Philip Mease, Herman Mielants. Arthritis Rheum 2006
33


Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.
Iain B McInnes, Proton Rahman, Alice B Gottlieb, Elizabeth C Hsia, Alexa P Kollmeier, Xie L Xu, Yusang Jiang, Shihong Sheng, May Shawi, Soumya D Chakravarty,[...]. Arthritis Rheumatol 2022
9
66

Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis.
Vinod Chandran, Sita Bhella, Catherine Schentag, Dafna D Gladman. Ann Rheum Dis 2007
120
27


The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials.
Richard G B Langley, Steven R Feldman, Judit Nyirady, Peter van de Kerkhof, Charis Papavassilis. J Dermatolog Treat 2015
123
27

Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Kristian Reich, April W Armstrong, Richard G Langley, Susan Flavin, Bruce Randazzo, Shu Li, Ming-Chun Hsu, Patrick Branigan, Andrew Blauvelt. Lancet 2019
137
22

Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Christian E Antoni, Arthur Kavanaugh, Bruce Kirkham, Zuhre Tutuncu, Gerd R Burmester, Udo Schneider, Daniel E Furst, Jerry Molitor, Edward Keystone, Dafna Gladman,[...]. Arthritis Rheum 2005
485
22

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
Iain B McInnes, Arthur Kavanaugh, Alice B Gottlieb, Lluís Puig, Proton Rahman, Christopher Ritchlin, Carrie Brodmerkel, Shu Li, Yuhua Wang, Alan M Mendelsohn,[...]. Lancet 2013
525
22


Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era.
Dafna D Gladman, Olga Ziouzina, Arane Thavaneswaran, Vinod Chandran. J Rheumatol 2013
60
22

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.
Jasvinder A Singh, Gordon Guyatt, Alexis Ogdie, Dafna D Gladman, Chad Deal, Atul Deodhar, Maureen Dubreuil, Jonathan Dunham, M Elaine Husni, Sarah Kenny,[...]. Arthritis Rheumatol 2019
185
22

Severe psoriasis--oral therapy with a new retinoid.
T Fredriksson, U Pettersson. Dermatologica 1978
22

Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis.
Philip J Mease, Iain B McInnes, Lai-Shan Tam, Kiefer Eaton, Steve Peterson, Agata Schubert, Soumya D Chakravarty, Anna Parackal, Chetan S Karyekar, Sandhya Nair,[...]. Rheumatology (Oxford) 2021
19
22





Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1.
Philip J Mease, Désirée van der Heijde, Christopher T Ritchlin, Masato Okada, Raquel S Cuchacovich, Catherine L Shuler, Chen-Yen Lin, Daniel K Braun, Chin H Lee, Dafna D Gladman. Ann Rheum Dis 2017
313
16

Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial.
Peter Nash, Bruce Kirkham, Masato Okada, Proton Rahman, Benard Combe, Gerd-Ruediger Burmester, David H Adams, Lisa Kerr, Chin Lee, Catherine L Shuler,[...]. Lancet 2017
224
16

A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative.
Laure Gossec, Maarten de Wit, Uta Kiltz, Juergen Braun, Umut Kalyoncu, Rossana Scrivo, Mara Maccarone, Laurence Carton, Kati Otsa, Imre Sooäär,[...]. Ann Rheum Dis 2014
210
16

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
Dafna Gladman, William Rigby, Valderilio F Azevedo, Frank Behrens, Ricardo Blanco, Andrzej Kaszuba, Elizabeth Kudlacz, Cunshan Wang, Sujatha Menon, Thijs Hendrikx,[...]. N Engl J Med 2017
253
16

International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials.
Ana-Maria Orbai, Maarten de Wit, Philip Mease, Judy A Shea, Laure Gossec, Ying Ying Leung, William Tillett, Musaab Elmamoun, Kristina Callis Duffin, Willemina Campbell,[...]. Ann Rheum Dis 2017
133
16

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor.
Arthur Kavanaugh, Philip J Mease, Juan J Gomez-Reino, Adewale O Adebajo, Jürgen Wollenhaupt, Dafna D Gladman, Eric Lespessailles, Stephen Hall, Marla Hochfeld, ChiaChi Hu,[...]. Ann Rheum Dis 2014
290
16

The psychosocial burden of psoriatic arthritis.
M Elaine Husni, Joseph F Merola, Sara Davin. Semin Arthritis Rheum 2017
81
16

The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies.
Arthur Kavanaugh, Alice Gottlieb, Akimichi Morita, Joseph F Merola, Chen-Yen Lin, Julie Birt, Catherine L Shuler, Matthew M Hufford, Diamant Thaçi. Ann Rheum Dis 2019
24
16

Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials.
Philip J Mease, Philip S Helliwell, Kasper Fjellhaugen Hjuler, Kyle Raymond, Iain McInnes. Ann Rheum Dis 2021
34
16

Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.
Philip J Mease, Apinya Lertratanakul, Jaclyn K Anderson, Kim Papp, Filip Van den Bosch, Shigeyoshi Tsuji, Eva Dokoupilova, Mauro Keiserman, Xin Wang, Sheng Zhong,[...]. Ann Rheum Dis 2021
56
16

The pathogenesis of psoriatic arthritis.
Douglas J Veale, Ursula Fearon. Lancet 2018
191
16

Switching biologics in the treatment of psoriatic arthritis.
Joseph F Merola, Benjamin Lockshin, Elinor A Mody. Semin Arthritis Rheum 2017
50
16

Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry.
Leslie R Harrold, Bradley S Stolshek, Sabrina Rebello, David H Collier, Alex Mutebi, Sally W Wade, Wendi Malley, Jeffrey D Greenberg, Carol J Etzel. Clin Rheumatol 2017
28
16

International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis.
Dafna D Gladman, Robert D Inman, Richard J Cook, Walter P Maksymowych, Jurgen Braun, John C Davis, Robert B M Landewé, Philip Mease, Joachim Brandt, Ruben Burgos Vargas,[...]. J Rheumatol 2007
99
16

Quality of life in psoriatic arthritis.
Tania Gudu, Laure Gossec. Expert Rev Clin Immunol 2018
70
16

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phase IIIb, randomised, controlled study (COSMOS).
Laura C Coates, Laure Gossec, Elke Theander, Paul Bergmans, Marlies Neuhold, Chetan S Karyekar, May Shawi, Wim Noël, Georg Schett, Iain B McInnes. Ann Rheum Dis 2022
6
50

Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults.
Wolf-Henning Boehncke, Nicolo Costantino Brembilla, Michael John Nissen. Expert Rev Clin Immunol 2021
13
23

Guselkumab demonstrated an independent treatment effect in reducing fatigue after adjustment for clinical response-results from two phase 3 clinical trials of 1120 patients with active psoriatic arthritis.
Proton Rahman, Philip J Mease, Philip S Helliwell, Atul Deodhar, Laure Gossec, Arthur Kavanaugh, Alexa P Kollmeier, Elizabeth C Hsia, Bei Zhou, Xiwu Lin,[...]. Arthritis Res Ther 2021
3
100

Treatment guidelines in psoriatic arthritis.
Alexis Ogdie, Laura C Coates, Dafna D Gladman. Rheumatology (Oxford) 2020
55
16

Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials.
Kristian Reich, Christopher E M Griffiths, Kenneth B Gordon, Kim A Papp, Michael Song, Bruce Randazzo, Shu Li, Yaung-Kaung Shen, Chenglong Han, Alexa B Kimball,[...]. J Am Acad Dermatol 2020
41
11

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.
L Gossec, J S Smolen, S Ramiro, M de Wit, M Cutolo, M Dougados, P Emery, R Landewé, S Oliver, D Aletaha,[...]. Ann Rheum Dis 2016
586
11

Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register.
Amr A Saad, Darren M Ashcroft, Kath D Watson, Kimme L Hyrich, Peter R Noyce, Deborah P M Symmons. Arthritis Res Ther 2009
153
11

Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1.
Christopher E M Griffiths, Kim A Papp, Michael Song, Megan Miller, Yin You, Yaung-Kaung Shen, Chenglong Han, Andrew Blauvelt. J Dermatolog Treat 2022
11
18

Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis.
John Bowes, Gisela Orozco, Edward Flynn, Pauline Ho, Rasha Brier, Helena Marzo-Ortega, Laura Coates, Ross McManus, Anthony W Ryan, David Kane,[...]. Ann Rheum Dis 2011
90
11

Real-world 2-year treatment patterns among patients with psoriatic arthritis treated with injectable biologic therapies.
Jessica A Walsh, Qian Cai, Iris Lin, Timothy Fitzgerald, Christopher D Pericone, Soumya D Chakravarty. Curr Med Res Opin 2020
8
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.